Curavit Expands Clinical Research Services by Acquiring Lindus Health Assets
Curavit Clinical Research has acquired assets from Lindus Health to expand its clinical research capabilities across the U.S. and Europe. The deal enhances the company's ability to execute trials for life science sponsors more rapidly.
Curavit Clinical Research has acquired assets from Lindus Health, aiming to solidify its position as a global provider of clinical research services. The transaction merges Curavit's U.S. and European operations, accelerating recruitment and broadening evidence-generation capabilities for sponsors in the pharmaceutical, biotechnology, medical technology, diagnostics, and digital health sectors.
The acquisition enables a unified approach to managing and executing clinical trials. This is intended to provide a significant advantage to life science sponsors seeking efficient pathways for bringing new treatments and devices to market. Curavit aims to offer a streamlined experience for conducting trials across international borders.
By integrating Lindus Health's European market experience with Curavit's U.S. infrastructure, the combined entity establishes a more robust global network. This synergy is expected to speed up patient recruitment and improve the reliability of trial data. The combined resources are set to support a wider scope of evidence generation and advance clinical research.
Curavit Clinical Research stated that the acquisition represents a strategic move to foster company growth and enhance its capacity to serve a larger client base. This expansion is designed to address the growing demand for efficient and globally integrated clinical trial solutions.